Acquired immunity to malaria

DL Doolan, C Dobaño, JK Baird - Clinical microbiology reviews, 2009 - journals.asm.org
Naturally acquired immunity to falciparum malaria protects millions of people routinely
exposed to Plasmodium falciparum infection from severe disease and death. There is no …

Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite

I Mueller, MR Galinski, JK Baird, JM Carlton… - The Lancet infectious …, 2009 - thelancet.com
Plasmodium vivax is geographically the most widely distributed cause of malaria in people,
with up to 2· 5 billion people at risk and an estimated 80 million to 300 million clinical cases …

Primaquine therapy for malaria

JK Baird, SL Hoffman - Clinical infectious diseases, 2004 - academic.oup.com
Primaquine is the only available drug for preventing relapse of malaria, and confusion
surrounds its use. This review examines the wide range of clinical applications of …

A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010

PW Gething, IRF Elyazar, CL Moyes, DL Smith… - 2012 - journals.plos.org
Background Current understanding of the spatial epidemiology and geographical
distribution of Plasmodium vivax is far less developed than that for P. falciparum …

The International Limits and Population at Risk of Plasmodium vivax Transmission in 2009

CA Guerra, RE Howes, AP Patil… - PLoS neglected …, 2010 - journals.plos.org
Background A research priority for Plasmodium vivax malaria is to improve our
understanding of the spatial distribution of risk and its relationship with the burden of P. vivax …

G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map

RE Howes, FB Piel, AP Patil, OA Nyangiri… - PLoS …, 2012 - journals.plos.org
Background Primaquine is a key drug for malaria elimination. In addition to being the only
drug active against the dormant relapsing forms of Plasmodium vivax, primaquine is the sole …

Global epidemiology of Plasmodium vivax

RE Howes, KE Battle, KN Mendis… - … American journal of …, 2016 - pmc.ncbi.nlm.nih.gov
Plasmodium vivax is the most widespread human malaria, putting 2.5 billion people at risk of
infection. Its unique biological and epidemiological characteristics pose challenges to …

Effectiveness of antimalarial drugs

JK Baird - New England Journal of Medicine, 2005 - Mass Medical Soc
A global resurgence of malaria has taken place as a result of a lapse in preventive efforts
and the emergence of resistance to standard antimalarial drugs. New therapies are …

Evidence and implications of mortality associated with acute Plasmodium vivax malaria

JK Baird - Clinical microbiology reviews, 2013 - journals.asm.org
Vivax malaria threatens patients despite relatively low-grade parasitemias in peripheral
blood. The tenet of death as a rare outcome, derived from antiquated and flawed clinical …

Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis

RN Price, L Von Seidlein, N Valecha… - The Lancet infectious …, 2014 - thelancet.com
Background Chloroquine is the first-line treatment for Plasmodium vivax malaria in most
endemic countries, but resistance is increasing. Monitoring of antimalarial efficacy is …